Theresa H. Gibble, PhD, MPH, MS

Eli Lilly & Company
Indianapolis, IN, United States

Theresa Hunter Gibble, PhD, MPH, MS is a Director on the Cardiometabolic Health HEOR team at Eli Lilly and Company.
Theresa Hunter Gibble, PhD, MPH, MS is a Director on the Cardiometabolic Health HEOR team at Eli Lilly and Company.
Theresa Hunter Gibble, PhD, MPH, MS is a Director on the Cardiometabolic Health HEOR team at Eli Lilly and Company.

Disclosure information not submitted.

Presentation(s):

• SAT-679 - 12-month Real-World Weight Loss with Tirzepatide among Individuals with Obesity/Overweight who switched from Semaglutide

  Saturday, June 13, 2026
  9:30 AM - 4:30 PM CT

• SAT-680 - BMI Category Shifts following Tirzepatide Persistent Use among Adults with Overweight or Obesity without Diabetes

  Saturday, June 13, 2026
  9:30 AM - 4:30 PM CT

• SAT-681 - Tirzepatide Persistence and Adherence Post Supply Shortage by Payer Type among Individuals with Obesity/Overweight and without Diabetes

  Saturday, June 13, 2026
  9:30 AM - 4:30 PM CT

• MON-232 - Real-World Treatment Patterns and Goals of Adolescents Living with Obesity in the US Population: Results from a Multinational Cross-sectional Survey (UNICORN)

  Monday, June 15, 2026
  9:00 AM - 2:00 PM CT

• MON-727 - Participant-Reported Weight Reduction and Reasons for Continuing or Discontinuing Tirzepatide Treatment: Insights from the PERCEPTIONS Longitudinal Survey at 3 Months

  Monday, June 15, 2026
  9:00 AM - 2:00 PM CT

• MON-728 - Patient-reported improvements in appetite control, quality of life, and work-related outcomes following tirzepatide treatment for obesity or overweight in the US: Results from 3-month PERCEPTIONS survey

  Monday, June 15, 2026
  9:00 AM - 2:00 PM CT